希少血友病因子の世界市場、2024～2028年

希少血友病因子市場は2023～2028年に2億860万米ドル、予測期間中のCAGRは10.04％で成長すると予測されます。

当レポートでは、希少血友病因子市場の全体的な分析、市場規模・予測、動向、成長促進要因、課題、約25のベンダーを網羅したベンダー分析などを掲載しています。

現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。同市場は、新たな治療技術の承認、費用対効果が高く高品質な医療ソリューションの採用、政府の積極的な取り組みなどによって牽引されています。

本調査では、遺伝子治療の登場が今後数年間の希少血友病因子市場成長を牽引する主要因の1つであるとしています。また、治療を開発するための技術革新や新規戦略のR&Dの増加は、市場の大きな需要につながります。

目次

第1章 エグゼクティブサマリー

• 市場概要

第2章 市場情勢

• 市場エコシステム
• 市場の特徴
• バリューチェーン分析

第3章 市場規模の評価

• 市場の定義
• 市場セグメント分析
• 市場規模 2023年
• 市場の展望 2023～2028年

第4章 市場規模実績

• 希少血友病因子の世界市場 2018～2022年
• 方法別セグメント分析 2018～2022年
• 地域別セグメント分析 2018～2022年
• 国別セグメント分析 2018～2022年

第5章 ファイブフォース分析

• ファイブフォースの要約
• 買い手の交渉力
• 供給企業の交渉力
• 新規参入業者の脅威
• 代替品の脅威
• 競争の脅威
• 市況

第6章 市場セグメンテーション：方法別

• 市場セグメンテーション
• 比較：方法別
• 新鮮凍結血漿：市場規模と予測 2023～2028年
• 因子濃縮物：市場規模と予測 2023～2028年
• クリオプレシピテート：市場規模と予測 2023～2028年
• その他：市場規模と予測 2023～2028年
• 市場機会：方法別

第7章 顧客情勢

• 顧客情勢概要

第8章 地域別情勢

• 地域別セグメンテーション
• 比較：地域別
• 北米：市場規模と予測 2023～2028年
• 欧州：市場規模と予測 2023～2028年
• アジア：市場規模と予測 2023～2028年
• その他：市場規模と予測 2023～2028年
• 米国：市場規模と予測 2023～2028年
• ドイツ：市場規模と予測 2023～2028年
• 英国：市場規模と予測 2023～2028年
• カナダ：市場規模と予測 2023～2028年
• 日本：市場規模と予測 2023～2028年
• 市場機会：地域情勢別

第9章 促進要因・課題・機会・抑制要因

• 市場促進要因
• 市場課題
• 促進要因と課題の影響
• 市場の機会・抑制要因

第10章 競合情勢

• 概要
• 競合情勢
• 混乱の状況
• 業界のリスク

第11章 競合分析

• 企業プロファイル
• 企業の市場ポジショニング
• Aptevo Therapeutics Inc.
• Bayer AG
• CSL Ltd.
• F. Hoffmann La Roche Ltd.
• Grifols SA
• Novo Nordisk AS
• Octapharma AG
• Pfizer Inc.
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd.

第12章 付録

Exhibits:

• Exhibits1: Executive Summary - Chart on Market Overview
• Exhibits2: Executive Summary - Data Table on Market Overview
• Exhibits3: Executive Summary - Chart on Global Market Characteristics
• Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
• Exhibits5: Executive Summary - Chart on Market Segmentation by Method
• Exhibits6: Executive Summary - Chart on Incremental Growth
• Exhibits7: Executive Summary - Data Table on Incremental Growth
• Exhibits8: Executive Summary - Chart on Company Market Positioning
• Exhibits9: Parent Market
• Exhibits10: Data Table on - Parent Market
• Exhibits11: Market characteristics analysis
• Exhibits12: Value Chain Analysis
• Exhibits13: Offerings of companies included in the market definition
• Exhibits14: Market segments
• Exhibits15: Chart on Global - Market size and forecast 2023-2028 ($ million)
• Exhibits16: Data Table on Global - Market size and forecast 2023-2028 ($ million)
• Exhibits17: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibits18: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibits19: Historic Market Size - Data Table on Global Rare Hemophilia Factors Market 2018 - 2022 ($ million)
• Exhibits20: Historic Market Size - Method Segment 2018 - 2022 ($ million)
• Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
• Exhibits22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
• Exhibits23: Five forces analysis - Comparison between 2023 and 2028
• Exhibits24: Bargaining power of buyers - Impact of key factors 2023 and 2028
• Exhibits25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• Exhibits26: Threat of new entrants - Impact of key factors in 2023 and 2028
• Exhibits27: Threat of substitutes - Impact of key factors in 2023 and 2028
• Exhibits28: Threat of rivalry - Impact of key factors in 2023 and 2028
• Exhibits29: Chart on Market condition - Five forces 2023 and 2028
• Exhibits30: Chart on Method - Market share 2023-2028 (%)
• Exhibits31: Data Table on Method - Market share 2023-2028 (%)
• Exhibits32: Chart on Comparison by Method
• Exhibits33: Data Table on Comparison by Method
• Exhibits34: Chart on Fresh frozen plasma - Market size and forecast 2023-2028 ($ million)
• Exhibits35: Data Table on Fresh frozen plasma - Market size and forecast 2023-2028 ($ million)
• Exhibits36: Chart on Fresh frozen plasma - Year-over-year growth 2023-2028 (%)
• Exhibits37: Data Table on Fresh frozen plasma - Year-over-year growth 2023-2028 (%)
• Exhibits38: Chart on Factor concentrates - Market size and forecast 2023-2028 ($ million)
• Exhibits39: Data Table on Factor concentrates - Market size and forecast 2023-2028 ($ million)
• Exhibits40: Chart on Factor concentrates - Year-over-year growth 2023-2028 (%)
• Exhibits41: Data Table on Factor concentrates - Year-over-year growth 2023-2028 (%)
• Exhibits42: Chart on Cryoprecipitate - Market size and forecast 2023-2028 ($ million)
• Exhibits43: Data Table on Cryoprecipitate - Market size and forecast 2023-2028 ($ million)
• Exhibits44: Chart on Cryoprecipitate - Year-over-year growth 2023-2028 (%)
• Exhibits45: Data Table on Cryoprecipitate - Year-over-year growth 2023-2028 (%)
• Exhibits46: Chart on Others - Market size and forecast 2023-2028 ($ million)
• Exhibits47: Data Table on Others - Market size and forecast 2023-2028 ($ million)
• Exhibits48: Chart on Others - Year-over-year growth 2023-2028 (%)
• Exhibits49: Data Table on Others - Year-over-year growth 2023-2028 (%)
• Exhibits50: Market opportunity by Method ($ million)
• Exhibits51: Data Table on Market opportunity by Method ($ million)
• Exhibits52: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• Exhibits53: Chart on Market share By Geographical Landscape 2023-2028 (%)
• Exhibits54: Data Table on Market share By Geographical Landscape 2023-2028 (%)
• Exhibits55: Chart on Geographic comparison
• Exhibits56: Data Table on Geographic comparison
• Exhibits57: Chart on North America - Market size and forecast 2023-2028 ($ million)
• Exhibits58: Data Table on North America - Market size and forecast 2023-2028 ($ million)
• Exhibits59: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibits60: Data Table on North America - Year-over-year growth 2023-2028 (%)
• Exhibits61: Chart on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibits62: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibits63: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibits64: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• Exhibits65: Chart on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibits66: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibits67: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibits68: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• Exhibits69: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibits70: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibits71: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibits72: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibits73: Chart on US - Market size and forecast 2023-2028 ($ million)
• Exhibits74: Data Table on US - Market size and forecast 2023-2028 ($ million)
• Exhibits75: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibits76: Data Table on US - Year-over-year growth 2023-2028 (%)
• Exhibits77: Chart on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibits78: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibits79: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibits80: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• Exhibits81: Chart on UK - Market size and forecast 2023-2028 ($ million)
• Exhibits82: Data Table on UK - Market size and forecast 2023-2028 ($ million)
• Exhibits83: Chart on UK - Year-over-year growth 2023-2028 (%)
• Exhibits84: Data Table on UK - Year-over-year growth 2023-2028 (%)
• Exhibits85: Chart on Canada - Market size and forecast 2023-2028 ($ million)
• Exhibits86: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
• Exhibits87: Chart on Canada - Year-over-year growth 2023-2028 (%)
• Exhibits88: Data Table on Canada - Year-over-year growth 2023-2028 (%)
• Exhibits89: Chart on Japan - Market size and forecast 2023-2028 ($ million)
• Exhibits90: Data Table on Japan - Market size and forecast 2023-2028 ($ million)
• Exhibits91: Chart on Japan - Year-over-year growth 2023-2028 (%)
• Exhibits92: Data Table on Japan - Year-over-year growth 2023-2028 (%)
• Exhibits93: Market opportunity By Geographical Landscape ($ million)
• Exhibits94: Data Tables on Market opportunity By Geographical Landscape ($ million)
• Exhibits95: Impact of drivers and challenges in 2023 and 2028
• Exhibits96: Overview on criticality of inputs and factors of differentiation
• Exhibits97: Overview on factors of disruption
• Exhibits98: Impact of key risks on business
• Exhibits99: Companies covered
• Exhibits100: Matrix on companies position and classification
• Exhibits101: Aptevo Therapeutics Inc. - Overview
• Exhibits102: Aptevo Therapeutics Inc. - Product / Service
• Exhibits103: Aptevo Therapeutics Inc. - Key offerings
• Exhibits104: Bayer AG - Overview
• Exhibits105: Bayer AG - Business segments
• Exhibits106: Bayer AG - Key news
• Exhibits107: Bayer AG - Key offerings
• Exhibits108: Bayer AG - Segment focus
• Exhibits109: CSL Ltd. - Overview
• Exhibits110: CSL Ltd. - Business segments
• Exhibits111: CSL Ltd. - Key news
• Exhibits112: CSL Ltd. - Key offerings
• Exhibits113: CSL Ltd. - Segment focus
• Exhibits114: F. Hoffmann La Roche Ltd. - Overview
• Exhibits115: F. Hoffmann La Roche Ltd. - Business segments
• Exhibits116: F. Hoffmann La Roche Ltd. - Key news
• Exhibits117: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibits118: F. Hoffmann La Roche Ltd. - Segment focus
• Exhibits119: Grifols SA - Overview
• Exhibits120: Grifols SA - Business segments
• Exhibits121: Grifols SA - Key news
• Exhibits122: Grifols SA - Key offerings
• Exhibits123: Grifols SA - Segment focus
• Exhibits124: Novo Nordisk AS - Overview
• Exhibits125: Novo Nordisk AS - Business segments
• Exhibits126: Novo Nordisk AS - Key news
• Exhibits127: Novo Nordisk AS - Key offerings
• Exhibits128: Novo Nordisk AS - Segment focus
• Exhibits129: Octapharma AG - Overview
• Exhibits130: Octapharma AG - Product / Service
• Exhibits131: Octapharma AG - Key offerings
• Exhibits132: Pfizer Inc. - Overview
• Exhibits133: Pfizer Inc. - Product / Service
• Exhibits134: Pfizer Inc. - Key news
• Exhibits135: Pfizer Inc. - Key offerings
• Exhibits136: Sanofi SA - Overview
• Exhibits137: Sanofi SA - Business segments
• Exhibits138: Sanofi SA - Key news
• Exhibits139: Sanofi SA - Key offerings
• Exhibits140: Sanofi SA - Segment focus
• Exhibits141: Takeda Pharmaceutical Co. Ltd. - Overview
• Exhibits142: Takeda Pharmaceutical Co. Ltd. - Product / Service
• Exhibits143: Takeda Pharmaceutical Co. Ltd. - Key news
• Exhibits144: Takeda Pharmaceutical Co. Ltd. - Key offerings
• Exhibits145: Inclusions checklist
• Exhibits146: Exclusions checklist
• Exhibits147: Currency conversion rates for US$
• Exhibits148: Research methodology
• Exhibits149: Information sources
• Exhibits150: Data validation
• Exhibits151: Validation techniques employed for market sizing
• Exhibits152: Data synthesis
• Exhibits153: 360 degree market analysis
• Exhibits154: List of abbreviations

The rare hemophilia factors market is forecasted to grow by USD 208.6 mn during 2023-2028, accelerating at a CAGR of 10.04% during the forecast period. The report on the rare hemophilia factors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by approval of new treatment techniques, introduction of cost-effective and high-quality medical solutions, and favorable government initiatives.

Technavio's rare hemophilia factors market is segmented as below:

By Method

• Fresh frozen plasma
• Factor concentrates
• Cryoprecipitate
• Others

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the advent of gene therapy as one of the prime reasons driving the rare hemophilia factors market growth during the next few years. Also, increase in technological innovations and R and D of novel strategies to develop therapeutics will lead to sizable demand in the market.

The report on the rare hemophilia factors market covers the following areas:

• Rare hemophilia factors market sizing
• Rare hemophilia factors market forecast
• Rare hemophilia factors market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading rare hemophilia factors market vendors that include Alnylam Pharmaceuticals Inc., Aptevo Therapeutics Inc., Bayer AG, Bio Products Laboratory Ltd., CSL Ltd., F. Hoffmann La Roche Ltd., Genentech Inc., Grifols SA, Gyre Therapeutics Inc., Intermountain Healthcare, Kedrion Spa, Novo Nordisk AS, Octapharma AG, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., The Johns Hopkins Health System Corp., UCSF Health, uniQure NV, and Versiti. Also, the rare hemophilia factors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market By Geographical Landscape
  • Executive Summary - Chart on Market Segmentation by Method
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
  • Parent Market
  • Data Table on - Parent Market
• 2.2 Market characteristics
  • Market characteristics analysis
• 2.3 Value chain analysis
  • Value Chain Analysis

3 Market Sizing

• 3.1 Market definition
  • Offerings of companies included in the market definition
• 3.2 Market segment analysis
  • Market segments
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028
  • Chart on Global - Market size and forecast 2023-2028 ($ million)
  • Data Table on Global - Market size and forecast 2023-2028 ($ million)
  • Chart on Global Market: Year-over-year growth 2023-2028 (%)
  • Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

• 4.1 Global Rare Hemophilia Factors Market 2018 - 2022
  • Historic Market Size - Data Table on Global Rare Hemophilia Factors Market 2018 - 2022 ($ million)
• 4.2 Method segment analysis 2018 - 2022
  • Historic Market Size - Method Segment 2018 - 2022 ($ million)
• 4.3 Geography segment analysis 2018 - 2022
  • Historic Market Size - Geography Segment 2018 - 2022 ($ million)
• 4.4 Country segment analysis 2018 - 2022
  • Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
  • Five forces analysis - Comparison between 2023 and 2028
• 5.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2023 and 2028
• 5.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• 5.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2023 and 2028
• 5.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2023 and 2028
• 5.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2023 and 2028
• 5.7 Market condition
  • Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Method

• 6.1 Market segments
  • Chart on Method - Market share 2023-2028 (%)
  • Data Table on Method - Market share 2023-2028 (%)
• 6.2 Comparison by Method
  • Chart on Comparison by Method
  • Data Table on Comparison by Method
• 6.3 Fresh frozen plasma - Market size and forecast 2023-2028
  • Chart on Fresh frozen plasma - Market size and forecast 2023-2028 ($ million)
  • Data Table on Fresh frozen plasma - Market size and forecast 2023-2028 ($ million)
  • Chart on Fresh frozen plasma - Year-over-year growth 2023-2028 (%)
  • Data Table on Fresh frozen plasma - Year-over-year growth 2023-2028 (%)
• 6.4 Factor concentrates - Market size and forecast 2023-2028
  • Chart on Factor concentrates - Market size and forecast 2023-2028 ($ million)
  • Data Table on Factor concentrates - Market size and forecast 2023-2028 ($ million)
  • Chart on Factor concentrates - Year-over-year growth 2023-2028 (%)
  • Data Table on Factor concentrates - Year-over-year growth 2023-2028 (%)
• 6.5 Cryoprecipitate - Market size and forecast 2023-2028
  • Chart on Cryoprecipitate - Market size and forecast 2023-2028 ($ million)
  • Data Table on Cryoprecipitate - Market size and forecast 2023-2028 ($ million)
  • Chart on Cryoprecipitate - Year-over-year growth 2023-2028 (%)
  • Data Table on Cryoprecipitate - Year-over-year growth 2023-2028 (%)
• 6.6 Others - Market size and forecast 2023-2028
  • Chart on Others - Market size and forecast 2023-2028 ($ million)
  • Data Table on Others - Market size and forecast 2023-2028 ($ million)
  • Chart on Others - Year-over-year growth 2023-2028 (%)
  • Data Table on Others - Year-over-year growth 2023-2028 (%)
• 6.7 Market opportunity by Method
  • Market opportunity by Method ($ million)
  • Data Table on Market opportunity by Method ($ million)

7 Customer Landscape

• 7.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

8 Geographic Landscape

• 8.1 Geographic segmentation
  • Chart on Market share By Geographical Landscape 2023-2028 (%)
  • Data Table on Market share By Geographical Landscape 2023-2028 (%)
• 8.2 Geographic comparison
  • Chart on Geographic comparison
  • Data Table on Geographic comparison
• 8.3 North America - Market size and forecast 2023-2028
  • Chart on North America - Market size and forecast 2023-2028 ($ million)
  • Data Table on North America - Market size and forecast 2023-2028 ($ million)
  • Chart on North America - Year-over-year growth 2023-2028 (%)
  • Data Table on North America - Year-over-year growth 2023-2028 (%)
• 8.4 Europe - Market size and forecast 2023-2028
  • Chart on Europe - Market size and forecast 2023-2028 ($ million)
  • Data Table on Europe - Market size and forecast 2023-2028 ($ million)
  • Chart on Europe - Year-over-year growth 2023-2028 (%)
  • Data Table on Europe - Year-over-year growth 2023-2028 (%)
• 8.5 Asia - Market size and forecast 2023-2028
  • Chart on Asia - Market size and forecast 2023-2028 ($ million)
  • Data Table on Asia - Market size and forecast 2023-2028 ($ million)
  • Chart on Asia - Year-over-year growth 2023-2028 (%)
  • Data Table on Asia - Year-over-year growth 2023-2028 (%)
• 8.6 Rest of World (ROW) - Market size and forecast 2023-2028
  • Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
  • Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
  • Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
  • Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• 8.7 US - Market size and forecast 2023-2028
  • Chart on US - Market size and forecast 2023-2028 ($ million)
  • Data Table on US - Market size and forecast 2023-2028 ($ million)
  • Chart on US - Year-over-year growth 2023-2028 (%)
  • Data Table on US - Year-over-year growth 2023-2028 (%)
• 8.8 Germany - Market size and forecast 2023-2028
  • Chart on Germany - Market size and forecast 2023-2028 ($ million)
  • Data Table on Germany - Market size and forecast 2023-2028 ($ million)
  • Chart on Germany - Year-over-year growth 2023-2028 (%)
  • Data Table on Germany - Year-over-year growth 2023-2028 (%)
• 8.9 UK - Market size and forecast 2023-2028
  • Chart on UK - Market size and forecast 2023-2028 ($ million)
  • Data Table on UK - Market size and forecast 2023-2028 ($ million)
  • Chart on UK - Year-over-year growth 2023-2028 (%)
  • Data Table on UK - Year-over-year growth 2023-2028 (%)
• 8.10 Canada - Market size and forecast 2023-2028
  • Chart on Canada - Market size and forecast 2023-2028 ($ million)
  • Data Table on Canada - Market size and forecast 2023-2028 ($ million)
  • Chart on Canada - Year-over-year growth 2023-2028 (%)
  • Data Table on Canada - Year-over-year growth 2023-2028 (%)
• 8.11 Japan - Market size and forecast 2023-2028
  • Chart on Japan - Market size and forecast 2023-2028 ($ million)
  • Data Table on Japan - Market size and forecast 2023-2028 ($ million)
  • Chart on Japan - Year-over-year growth 2023-2028 (%)
  • Data Table on Japan - Year-over-year growth 2023-2028 (%)
• 8.12 Market opportunity By Geographical Landscape
  • Market opportunity By Geographical Landscape ($ million)
  • Data Tables on Market opportunity By Geographical Landscape ($ million)

9 Drivers, Challenges, and Opportunity/Restraints

• 9.1 Market drivers
• 9.2 Market challenges
• 9.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2023 and 2028
• 9.4 Market opportunities/restraints

10 Competitive Landscape

• 10.1 Overview
• 10.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 10.3 Landscape disruption
  • Overview on factors of disruption
• 10.4 Industry risks
  • Impact of key risks on business

11 Competitive Analysis

• 11.1 Companies profiled
  • Companies covered
• 11.2 Market positioning of companies
  • Matrix on companies position and classification
• 11.3 Aptevo Therapeutics Inc.
  • Aptevo Therapeutics Inc. - Overview
  • Aptevo Therapeutics Inc. - Product / Service
  • Aptevo Therapeutics Inc. - Key offerings
• 11.4 Bayer AG
  • Bayer AG - Overview
  • Bayer AG - Business segments
  • Bayer AG - Key news
  • Bayer AG - Key offerings
  • Bayer AG - Segment focus
• 11.5 CSL Ltd.
  • CSL Ltd. - Overview
  • CSL Ltd. - Business segments
  • CSL Ltd. - Key news
  • CSL Ltd. - Key offerings
  • CSL Ltd. - Segment focus
• 11.6 F. Hoffmann La Roche Ltd.
  • F. Hoffmann La Roche Ltd. - Overview
  • F. Hoffmann La Roche Ltd. - Business segments
  • F. Hoffmann La Roche Ltd. - Key news
  • F. Hoffmann La Roche Ltd. - Key offerings
  • F. Hoffmann La Roche Ltd. - Segment focus
• 11.7 Grifols SA
  • Grifols SA - Overview
  • Grifols SA - Business segments
  • Grifols SA - Key news
  • Grifols SA - Key offerings
  • Grifols SA - Segment focus
• 11.8 Novo Nordisk AS
  • Novo Nordisk AS - Overview
  • Novo Nordisk AS - Business segments
  • Novo Nordisk AS - Key news
  • Novo Nordisk AS - Key offerings
  • Novo Nordisk AS - Segment focus
• 11.9 Octapharma AG
  • Octapharma AG - Overview
  • Octapharma AG - Product / Service
  • Octapharma AG - Key offerings
• 11.10 Pfizer Inc.
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Product / Service
  • Pfizer Inc. - Key news
  • Pfizer Inc. - Key offerings
• 11.11 Sanofi SA
  • Sanofi SA - Overview
  • Sanofi SA - Business segments
  • Sanofi SA - Key news
  • Sanofi SA - Key offerings
  • Sanofi SA - Segment focus
• 11.12 Takeda Pharmaceutical Co. Ltd.
  • Takeda Pharmaceutical Co. Ltd. - Overview
  • Takeda Pharmaceutical Co. Ltd. - Product / Service
  • Takeda Pharmaceutical Co. Ltd. - Key news
  • Takeda Pharmaceutical Co. Ltd. - Key offerings

12 Appendix

• 12.1 Scope of the report
• 12.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 12.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 12.4 Research methodology
  • Research methodology
• 12.5 Data procurement
  • Information sources
• 12.6 Data validation
  • Data validation
• 12.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 12.8 Data synthesis
  • Data synthesis
• 12.9 360 degree market analysis
  • 360 degree market analysis
• 12.10 List of abbreviations
  • List of abbreviations